# Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

> **NCT07152223** · NA · RECRUITING · sponsor: **Guangzhou Bio-gene Technology Co., Ltd** · enrollment: 20 (estimated)

## Conditions studied

- Connective Tissue Diseases

## Interventions

- **BIOLOGICAL:** CAR-T

## Key facts

- **NCT ID:** NCT07152223
- **Lead sponsor:** Guangzhou Bio-gene Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-30
- **Primary completion:** 2029-08-31
- **Final completion:** 2029-08-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07152223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07152223, "Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07152223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*